The opioid antagonist naltrexone decreases seizure‐like activity in genetic and chemically induced epilepsy models
Sign Up to like & getrecommendations! Published in 2021 at "Epilepsia Open"
DOI: 10.1002/epi4.12512
Abstract: A significant number of epileptic patients fail to respond to available anticonvulsive medications. To find new anticonvulsive medications, we evaluated FDA‐approved drugs not known to be anticonvulsants. Using zebrafish larvae as an initial model system,… read more here.
Keywords: naltrexone decreases; antagonist naltrexone; epilepsy models; opioid antagonist ... See more keywords
Opioid Antagonist Nanodrugs Successfully Attenuate the Severity of Ischemic Stroke
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00079
Abstract: The United States is in the midst of an opioid epidemic that is linked to a number of serious health issues, including an increase in cerebrovascular events, namely, stroke. Chronic prescription opioid use exacerbates the… read more here.
Keywords: opioid antagonist; severity ischemic; opioid antagonists; stroke ... See more keywords
Dose Escalation of Naltrexone to Reduce Stress Responses Associated With Opioid Antagonist Induction: A Double-blind Randomized Trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Addiction Medicine"
DOI: 10.1097/adm.0000000000000560
Abstract: CONTEXT To describe the role of opioid antagonist induction in reducing stress response and withdrawal symptoms. OBJECTIVE Complexity of naltrexone induction is limiting broader applicability of opioid antagonist-assisted abstinence. The aim of this clinical trial… read more here.
Keywords: dose; antagonist induction; opioid antagonist; induction ... See more keywords